Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in Adenoid Cystic Carcinoma
NCT01417143Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in adenoid cystic carcinoma (ACC), sponsored by Seoul National University Hospital. Primary endpoint: Progression Free Survival at 4 months. Started Sep 2011; status: completed.
02
Drugs
dovitinib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT01417143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417143.